216 related articles for article (PubMed ID: 23031786)
1. Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer.
Lin H; Huang JF; Qiu JR; Zhang HL; Tang XJ; Li H; Wang CJ; Wang ZC; Feng ZQ; Zhu J
Exp Mol Pathol; 2013 Feb; 94(1):73-8. PubMed ID: 23031786
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.
Xu X; Tang X; Lu M; Tang Q; Zhang H; Zhu H; Xu N; Zhang D; Xiong L; Mao Y; Zhu J
Exp Mol Pathol; 2014 Dec; 97(3):579-84. PubMed ID: 25445503
[TBL] [Abstract][Full Text] [Related]
3. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
[TBL] [Abstract][Full Text] [Related]
4. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters.
Ravikumar G; Ananthamurthy A
J Cancer Res Ther; 2014; 10(3):671-5. PubMed ID: 25313758
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype.
Mylona E; Tzelepis K; Theohari I; Giannopoulou I; Papadimitriou C; Nakopoulou L
Histopathology; 2013 Feb; 62(3):472-80. PubMed ID: 23163571
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.
Li R; An SJ; Chen ZH; Zhang GC; Zhu JQ; Nie Q; Xie Z; Guo AL; Mok TS; Wu YL
Hum Pathol; 2008 Dec; 39(12):1792-801. PubMed ID: 18715616
[TBL] [Abstract][Full Text] [Related]
8. Role of COX-2, VEGF and cyclin D1 in mammary infiltrating duct carcinoma.
Lim SC
Oncol Rep; 2003; 10(5):1241-9. PubMed ID: 12883688
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
10. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma.
Pula B; Jethon A; Piotrowska A; Gomulkiewicz A; Owczarek T; Calik J; Wojnar A; Witkiewicz W; Rys J; Ugorski M; Dziegiel P; Podhorska-Okolow M
Histopathology; 2011 Dec; 59(6):1249-60. PubMed ID: 22175904
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of cyclin D1, β-catenin, and MTA1 in patients with invasive ductal carcinoma of the breast.
Cheng CW; Liu YF; Yu JC; Wang HW; Ding SL; Hsiung CN; Hsu HM; Shieh JC; Wu PE; Shen CY
Ann Surg Oncol; 2012 Dec; 19(13):4129-39. PubMed ID: 22864797
[TBL] [Abstract][Full Text] [Related]
12. Inhibin/activin subunits (inhibin-alpha, -betaA and -betaB) are differentially expressed in human breast cancer and their metastasis.
Mylonas I; Jeschke U; Shabani N; Kuhn C; Friese K; Gerber B
Oncol Rep; 2005 Jan; 13(1):81-8. PubMed ID: 15583806
[TBL] [Abstract][Full Text] [Related]
13. [Expression and Significance of BP1 Gene and Cyclin D1 Gene in Breast Cancer].
Song YC; Fu SD; Wen XP; Ma ZH; Dang CX
Ai Zheng; 2007 Jul; 26(7):709-14. PubMed ID: 17626745
[TBL] [Abstract][Full Text] [Related]
14. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer.
Lim SC; Lee MS
Oncol Rep; 2002; 9(5):915-28. PubMed ID: 12168049
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of cyclin D1 in breast cancer.
Bilalović N; Vranić S; Basić H; Tatarević A; Selak I
Croat Med J; 2005 Jun; 46(3):382-8. PubMed ID: 15861516
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.
Xiao M; Xu Q; Lou C; Qin Y; Ning X; Liu T; Zhao X; Jia S; Huang Y
Hum Pathol; 2017 Apr; 62():40-49. PubMed ID: 28087477
[TBL] [Abstract][Full Text] [Related]
18. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
19. Automated image analysis of cyclin D1 protein expression in invasive lobular breast carcinoma provides independent prognostic information.
Tobin NP; Lundgren KL; Conway C; Anagnostaki L; Costello S; Landberg G
Hum Pathol; 2012 Nov; 43(11):2053-61. PubMed ID: 22647349
[TBL] [Abstract][Full Text] [Related]
20. Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome.
Hsing CH; Cheng HC; Hsu YH; Chan CH; Yeh CH; Li CF; Chang MS
Clin Cancer Res; 2012 Feb; 18(3):713-25. PubMed ID: 22186257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
